Colgate-Palmolive Company logo

Colgate-Palmolive Company

CL

NYSEConsumer DefensiveHousehold & Personal Products

Previous close

$91.08

+$1.38 · +1.54%

Aug 21, 4:00 PM ET

CL company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

48

Fair Value

Momentum

43

Neutral

Sentiment

72

Bullish

Risk resilience

80

Low Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Operating globally, Colgate-Palmolive Company and its affiliated entities are engaged in the production and distribution of a diverse range of consumer goods. Its operations are structured into two primary divisions: Oral, Personal and Home Care, and Pet Nutrition. The Oral, Personal and Home Care division encompasses a broad array of offerings, spanning oral hygiene (e.g., toothpastes, toothbrushes, mouthwashes), personal care (e.g., bar and liquid soaps, shower gels, shampoos, conditioners, deodorants, antiperspirants, skin health items), and home care solutions (e.g., dishwashing detergents, fabric conditioners, household cleaners). These products are distributed through various channels, including traditional and online retailers, wholesalers, and distributors, under well-known brand names such as Colgate, Darlie, elmex, hello, meridol, Sorriso, Tom's of Maine, Irish Spring, Palmolive, Protex, Sanex, Softsoap, Lady Speed Stick, Speed Stick, EltaMD, Filorga, PCA SKIN, Ajax, Axion, Fabuloso, Murphy, Suavitel, Soupline, and Cuddly. Furthermore, this segment supplies specialized pharmaceutical products to dentists and other professionals in oral healthcare. Conversely, the Pet Nutrition segment focuses on providing specialized pet food. This includes everyday nutritional options marketed under the Hill's Science Diet brand, as well as therapeutic diets designed to assist in managing various health conditions in dogs and cats, sold under the Hill's Prescription Diet brand. Distribution for these pet nutrition items occurs via pet supply stores, veterinary clinics, and online retail platforms. Established in 1806, Colgate-Palmolive Company maintains its corporate headquarters in New York, New York.

Industry
Household & Personal Products
Sector
Consumer Defensive
Headquarters
US
CEO
Noel R. Wallace
Listed since
May 2, 1973
Employees
33,600

Market position

Day range

Current $91.08

52-week range

Current $91.08

Open
$89.87
Previous close
$89.70
Volume
2.57M
0.51× average
Average volume
5.04M
Average daily volume
Market cap
72.88B USD
Beta
0.33
Market reference 1
50-day average
$91.7724
-0.75% below average
200-day average
$87.0986
+4.57% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
70.6B USD
P/E (TTM)
35.8×
P/B (TTM)
307.41×
P/S (TTM)
3.46×
EV / EBITDA
17.85×
Earnings yield
3.34%
Free cash flow yield
5.69%
Dividend yield
2.31%

Profitability & efficiency

Gross margin
60.42%
Operating margin
20.65%
Net margin
9.68%
Return on equity
3948.15%
Return on assets
13.06%
Return on invested capital
30.34%

Financial health

Debt / equity
33.29×
Current ratio
Altman Z-score
6.85
Piotroski F-score
8 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends65%45%25%5%Gross margin, FY2021: 59.08%Gross margin, FY2022: 56.49%Gross margin, FY2023: 57.82%Gross margin, FY2024: 60.23%Gross margin, FY2025: 60.11%Operating margin, FY2021: 22.31%Operating margin, FY2022: 19.95%Operating margin, FY2023: 21.23%Operating margin, FY2024: 21.80%Operating margin, FY2025: 21.33%Net margin, FY2021: 12.43%Net margin, FY2022: 9.93%Net margin, FY2023: 11.82%Net margin, FY2024: 14.37%Net margin, FY2025: 10.46%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 59.08%. Gross margin FY2022 56.49%. Gross margin FY2023 57.82%. Gross margin FY2024 60.23%. Gross margin FY2025 60.11%. Operating margin FY2021 22.31%. Operating margin FY2022 19.95%. Operating margin FY2023 21.23%. Operating margin FY2024 21.80%. Operating margin FY2025 21.33%. Net margin FY2021 12.43%. Net margin FY2022 9.93%. Net margin FY2023 11.82%. Net margin FY2024 14.37%. Net margin FY2025 10.46%.

Income trends

Revenue

20.38B USD+1.40%

Operating income

4.35B USD-0.80%

Net income

2.13B USD-26.20%
Income trends across reported periods22.24B USD14.8B USD7.36B USD−74.7M USDRevenue, FY2021: 17.42B USDRevenue, FY2022: 17.97B USDRevenue, FY2023: 19.46B USDRevenue, FY2024: 20.1B USDRevenue, FY2025: 20.38B USDOperating income, FY2021: 3.89B USDOperating income, FY2022: 3.59B USDOperating income, FY2023: 4.13B USDOperating income, FY2024: 4.38B USDOperating income, FY2025: 4.35B USDNet income, FY2021: 2.17B USDNet income, FY2022: 1.79B USDNet income, FY2023: 2.3B USDNet income, FY2024: 2.89B USDNet income, FY2025: 2.13B USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 17.42B USD. Revenue FY2022 17.97B USD. Revenue FY2023 19.46B USD. Revenue FY2024 20.1B USD. Revenue FY2025 20.38B USD. Operating income FY2021 3.89B USD. Operating income FY2022 3.59B USD. Operating income FY2023 4.13B USD. Operating income FY2024 4.38B USD. Operating income FY2025 4.35B USD. Net income FY2021 2.17B USD. Net income FY2022 1.79B USD. Net income FY2023 2.3B USD. Net income FY2024 2.89B USD. Net income FY2025 2.13B USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue20.38B USD20.1B USD19.46B USD17.97B USD17.42B USD
Cost of goods sold8.13B USD8B USD8.21B USD7.82B USD7.13B USD
Gross profit12.25B USD12.11B USD11.25B USD10.15B USD10.29B USD
Research and development355M USD343M USD320M USD307M USD
Selling, general, and administrative7.9B USD7.81B USD6.78B USD6.25B USD6.1B USD
Operating expenses7.9B USD7.72B USD7.12B USD6.57B USD6.41B USD
Interest income75M USD67M USD55M USD14M USD17M USD
Interest expense267M USD292M USD287M USD167M USD117M USD
Depreciation and amortization630M USD605M USD567M USD545M USD556M USD
Operating income4.35B USD4.38B USD4.13B USD3.59B USD3.89B USD
Net income2.13B USD2.89B USD2.3B USD1.79B USD2.17B USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
100%
11 beats, 0 misses, 0 met estimates
Average EPS surprise
+3.57%
11 comparable reports
Latest EPS result
0.99
Estimate 0.95 · Beat by 4.54%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates1.030.960.890.82Q1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Jan 31, 2025: actual 0.91, estimate 0.9, surprise +1.11%, Beat. Q2 2025, reported Apr 25, 2025: actual 0.91, estimate 0.856, surprise +6.31%, Beat. Q3 2025, reported Aug 1, 2025: actual 0.92, estimate 0.897, surprise +2.56%, Beat. Q4 2025, reported Oct 31, 2025: actual 0.91, estimate 0.889, surprise +2.36%, Beat. Q1 2026, reported Jan 30, 2026: actual 0.95, estimate 0.912, surprise +4.17%, Beat. Q2 2026, reported May 1, 2026: actual 0.97, estimate 0.943, surprise +2.86%, Beat. Q3 2026, reported Jul 31, 2026: actual 0.99, estimate 0.947, surprise +4.54%, Beat. Q4 2026, reported Oct 30, 2026: actual —, estimate 0.92, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates5.58B5.27B4.96B4.65BQ1 '25MissQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Jan 31, 2025: actual 4.95B USD, estimate 4.98B USD, surprise -0.69%, Miss. Q2 2025, reported Apr 25, 2025: actual 4.91B USD, estimate 4.87B USD, surprise +0.92%, Beat. Q3 2025, reported Aug 1, 2025: actual 5.11B USD, estimate 5.04B USD, surprise +1.48%, Beat. Q4 2025, reported Oct 31, 2025: actual 5.13B USD, estimate 5.13B USD, surprise +0.08%, Beat. Q1 2026, reported Jan 30, 2026: actual 5.23B USD, estimate 5.12B USD, surprise +2.09%, Beat. Q2 2026, reported May 1, 2026: actual 5.32B USD, estimate 5.22B USD, surprise +2.07%, Beat. Q3 2026, reported Jul 31, 2026: actual 5.36B USD, estimate 5.36B USD, surprise +0.09%, Beat. Q4 2026, reported Oct 30, 2026: actual —, estimate 5.34B USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

45 ratings
Strong buy00%
Buy1840%
Hold2556%
Sell24%
Strong sell00%

CL news

Corporate actions

Corporate action history

Stock split

Effective May 16, 2013

2:1

Stock split

Effective Jul 1, 1999

2:1

Stock split

Effective May 16, 1997

2:1

Stock split

Effective May 16, 1991

2:1

Stock split

Effective May 30, 1973

3:1

CL peers

ETFs holding CL

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research CL

research.disclaimer